Shopping Cart
Remove All
Your shopping cart is currently empty
BBO-10203 is an orally active small molecule, also designated as Compound 758, that functions as a selective PI3Kα-Ras interaction disruptor by binding to the Ras-binding domain of PI3Kα. BBO-10203 effectively prevents Ras-PI3Kα complex formation, inhibits downstream Akt activation without altering basal PI3Kα kinase activity, thereby minimizing risks of hyperglycemia and hyperinsulinemia, and displays selective antitumor activity against KRAS-mutant malignancies, making it an important investigational candidate for targeted cancer therapeutics.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,980 | - | In Stock | |
| 5 mg | $4,120 | - | In Stock | |
| 10 mg | $5,630 | - | In Stock | |
| 25 mg | $8,460 | - | In Stock |
| Description | BBO-10203 is an orally active small molecule, also designated as Compound 758, that functions as a selective PI3Kα-Ras interaction disruptor by binding to the Ras-binding domain of PI3Kα. BBO-10203 effectively prevents Ras-PI3Kα complex formation, inhibits downstream Akt activation without altering basal PI3Kα kinase activity, thereby minimizing risks of hyperglycemia and hyperinsulinemia, and displays selective antitumor activity against KRAS-mutant malignancies, making it an important investigational candidate for targeted cancer therapeutics. |
| In vitro | BBO-10203 blocks the interaction between KRAS-G12D and PI3Kα in HEK293T cells with an IC50 of 6 nM, without affecting the binding between KRAS-G12D and protein kinase CRAF or inhibiting the in vitro kinase activity of PI3Kα. BBO-10203 exhibits an IC50 < 10 nM against most HER2 gene-amplified cell lines and is sensitive to PIK3CA spiral mutations in cell lines. [1][2] |
| In vivo | In fasting male mice undergoing an oral glucose tolerance test, 300 mg/kg BBO-10203 did not affect glucose metabolism, while 50 mg/kg aprelis was associated with hyperglycaemia and hyperinsulinaemia.
In xenograft mouse models with KRAS G12X mutations, with or without PIK3CA mutations, BBO-10203 (10–100 mg/kg, oral, once daily, for 28 days) exhibited dose-dependent tumour volume reduction effects and antitumour efficacy in several subcutaneous xenograft models with multiple KRAS mutations. [1] |
| Synonyms | BBO10203 |
| Molecular Weight | 640.7 |
| Formula | C34H30F2N6O3S |
| Cas No. | 2971769-60-3 |
| Smiles | O=C(C=C)N1CCN2N=C(C=C2C1C)C=3N=C(C=4C=CC5=C(C=NN5C)C4)C=6C=CSC6C3C7=C(F)C=C(F)C=C7OCCOC |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (124.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.